Less Ads, More Data, More Tools Register for FREE

South Africa is promised 9 million J&J vaccine shots - Business Day

Mon, 18th Jan 2021 08:42

JOHANNESBURG, Jan 18 (Reuters) - South Africa, which has yet
to receive its first coronavirus vaccine, has been promised 9
million doses by Johnson & Johnson, the Business Day
newspaper reported on Monday, citing a health ministry
spokeswoman.

The government of Africa's most advanced economy is
scrambling to secure enough COVID-19 vaccines, after health
workers and scientists publicly criticised it for not moving
fast enough to inoculate its people.

The country has recorded more than 1.3 million infections
and more than 37,000 deaths related to the virus, the most in
Africa.

Business Day said the 9 million J&J doses took the total
amount of doses South Africa had been promised to more than 30
million. Roughly 12 million doses are coming from the COVAX
global vaccine distribution scheme, around 12 million from an
African Union arrangement, and 1.5 million from the Serum
Institute of India which is making AstraZeneca shots.

Health ministry spokeswoman Lwazi Manzi did not respond to
messages or a phone call seeking comment. J&J did not
immediately respond to an email seeking comment.

Anban Pillay, deputy director-general at the health
ministry, told Reuters that in addition to the 20 million doses
that President Cyril Ramaphosa said last week had been secured,
"additional doses have been secured but we cannot make
announcements until we close a couple of matters with the
suppliers".

The health ministry said earlier this month that it was in
advanced negotiations with J&J. Local pharmaceutical company
Aspen will be manufacturing J&J shots but unless a firm
agreement is signed with the South African government all those
doses will be exported.
(Reporting by Alexander Winning; Editing by Nick Macfie)

Related Shares

More News
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.